Your browser doesn't support javascript.
COVID-19 and Gut Injury.
Shen, Sj; Gong, Muxue; Wang, Gang; Dua, Kamal; Xu, Jincheng; Xu, Xiaoyue; Liu, Gang.
  • Shen S; UNSW Microbiome Research Centre, St George and Sutherland Clinical Campus, University of New South Wales, Sydney, NSW 2217, Australia.
  • Gong M; School of Clinical Medicine, Bengbu Medicine College, Bengbu 233030, China.
  • Wang G; Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Dua K; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • Xu J; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
  • Xu X; Stomatology Department, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
  • Liu G; School of Dental Medicine, Bengbu Medical College, Bengbu 233030, China.
Nutrients ; 14(20)2022 Oct 20.
Article in English | MEDLINE | ID: covidwho-2281057
ABSTRACT
COVID-19 induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a pandemic and it has led to more than 620 million patients with 6.56 million deaths globally. Males are more susceptible to COVID-19 infection and associated with a higher chance to develop severe COVID-19 than females. Aged people are at a high risk of COVID-19 infection, while young children have also increased cases. COVID-19 patients typically develop respiratory system pathologies, however symptoms in the gastrointestinal (GI) tract are also very common. Inflammatory cell recruitments and their secreted cytokines are found in the GI tract in COVID-19 patients. Microbiota changes are the key feature in COVID-19 patients with gut injury. Here, we review all current known mechanisms of COVID-19-induced gut injury, and the most acceptable one is that SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptor on host cells in the GI tract. Interestingly, inflammatory bowel disease (IBD) is an inflammatory disorder, but the patients with IBD do not have the increased risk to develop COVID-19. There is currently no cure for COVID-19, but anti-viruses and monoclonal antibodies reduce viral load and shorten the recovery time of the disease. We summarize current therapeutics that target symptoms in the GI tract, including probiotics, ACE2 inhibitors and nutrients. These are promising therapeutic options for COVID-19-induced gut injury.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Gastrointestinal Diseases / COVID-19 Type of study: Prognostic study Limits: Female / Humans / Male Language: English Year: 2022 Document Type: Article Affiliation country: Nu14204409

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Gastrointestinal Diseases / COVID-19 Type of study: Prognostic study Limits: Female / Humans / Male Language: English Year: 2022 Document Type: Article Affiliation country: Nu14204409